Abivax (ABVX) Total Current Liabilities (2021 - 2026)

Abivax's Total Current Liabilities history runs 6 years deep, the most recent figure standing at $72.9 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 34.5% year-over-year to $72.9 million; the TTM figure through Mar 2026 stood at $72.9 million (down 34.5% YoY), while the FY2025 annual figure was $73.4 million, down 26.97% from the prior year.
• Total Current Liabilities was $72.9 million for Q1 2026 at Abivax, down from $73.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $127.2 million in Q2 2025 to a low of $52.5 million in Q4 2022.
• Historically, Total Current Liabilities has averaged $90.4 million across 5 years, with a median of $92.1 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Total Current Liabilities jumped 85.85% in 2023, then slumped 34.5% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $52.5 million in 2022, then soared by 85.85% to $97.6 million in 2023, then grew by 2.94% to $100.4 million in 2024, then slipped by 26.97% to $73.4 million in 2025, then fell by 0.68% to $72.9 million in 2026.
• The last three Total Current Liabilities figures came in at $72.9 million (Q1 2026), $73.4 million (Q4 2025), and $92.1 million (Q3 2025), per Business Quant data.